

Apheresis Market Size by Product (Device (Centrifugation, Membrane Separation) Disposable), Procedure (Donor, Therapeutic), Application (Plasmapheresis, Plateletpheresis), Technology, End-User (Hospital, Blood Collection Center), Region - Global Forecast to 2029

Market Report | 2024-04-12 | 330 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global apheresis market is projected to reach USD 3.9 billion by 2029 from USD 2.6 billion in 2024, at a CAGR of 8.8% from 2024 to 2029. The growth of the market is driven by a rising incidence of trauma and injury cases, upsurging number of complex surgical procedure. The market also benefits from rise in investments from government bodies and key players and the surge in use of apheresis procedure for leukaemia and paediatric patients.

However, significant expenses associated with apheresis devices and therapeutic procedures, along with the option of installing apheresis devices via rental agreements, are impacting the industry. Moreover, decline in apheresis-based blood donations due to insufficient awareness among potential donors is a major factor restraining the market growth.

"Therapeutic apheresis disposables segment to witness the highest growth during the forecast period."

Based on procedure, the segment is divided into automated blood collection and therapeutic apheresis. The therapeutic apheresis is further divided into therapeutic apheresis disposables and therapeutic apheresis devices. The therapeutic apheresis disposables witness the highest growth in the apheresis market during the forecast period, attributing to rise in awareness about apheresis procedures, particularly for therapeutic purposes. This increased awareness has led to a growing acceptance of apheresis as an effective treatment option among healthcare providers and patients alike. Moreover, there is a significant increase in research activities focusing on apheresis procedures for therapeutic applications. This ongoing research is uncovering new insights into the efficacy and versatility of apheresis in treating various medical conditions, ranging from autoimmune disorders to hematologic malignancies. Thus, healthcare professionals are increasingly incorporating these procedures into their treatment protocols. As a result, the demand for therapeutic apheresis procedures is expected to surge in the coming years.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

"Continuous flow centrifugation segment accounted for the largest share in the apheresis market during the forecast period." Based on technology, the apheresis market is segmented into centrifugation, and membrane separation. The centrifugation segment is further divided into continuous flow centrifugation and intermittent flow centrifugation. Among these, the continuous flow centrifugation segment accounted for largest share in the apheresis market in 2023. As continuous flow centrifugation technology is highly preferred in both blood collection and therapeutic apheresis procedures due to its efficiency and effectiveness. This technology allows for a smoother and more consistent separation process, leading to higher yields of desired blood components. As a result, healthcare facilities and blood collection centers Favor continuous flow centrifugation systems to streamline their operations and improve overall productivity. Moreover, continuous flow centrifugation technology offers several distinct advantages, such as its ability to operate with a small extracorporeal volume (ECV), minimizing the patient's exposure to extracorporeal circulation. Additionally, this technology is associated with shorter procedural times and requires relatively low volumes of anticoagulants, which enhances patient safety and comfort. These advantages make continuous flow centrifugation a preferred choice among healthcare providers, thus increasing the market growth during forecasting period.

"APAC is estimated to register the highest CAGR during the forecast period."

In this report, the apheresis market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The market in APAC is projected to register the highest growth rate during the forecast period, attributing to expansion of healthcare infrastructure and blood banking facilities. This is due to increasing support from governments across the region for the development of healthcare infrastructure. These countries are growing economically thus, governments are allocating substantial resources towards enhancing healthcare services, including the establishment of modern medical facilities and the adoption of advanced medical technologies like apheresis devices. Moreover, increasing awareness of the importance of safe blood transfusions and the need for advanced blood collection and processing techniques, governments and healthcare authorities are incentivizing the expansion and modernization of blood banking facilities. Thus, increasing the government-licensed and accredited blood banks, leading to rise in the growth of apheresis market.

Breakdown of supply-side primary interviews, by company type, designation, and region:

- By Company Type: Tier 1 (20%), Tier 2 (45%), and Tier 3 (35%)
- By Designation: C-level (30%), Director-level (20%), and Others (50%)
- By Region: North America (35%), Europe (24%), Asia Pacific (25%), Latin America and Middle East Africa (16%)

List of Companies Profiled in the Report

- o Terumo BCT, Inc. (Japan)
- o Fresenius SE & Co. KGaA (Germany)
- o Haemonetics Corporation (US)
- o Baxter International Inc. (US)
- o Asahi Kasei Medical Co., Ltd. (Japan)
- o B. Braun Melsungen AG (Germany)
- o Cerus Corporation (US)
- o Kaneka Corporation (Japan)
- o SB-Kawasumi Laboratories, Inc (Japan)
- o Nikkiso Co., Ltd (Japan)
- o Macopharma SA (France)
- o Miltenyi Biotec (Germany)
- o Otsuka Holdings Co., Ltd. (Japan)
- o Medica S.p.A. (Italy)
- o Mallinckrodt plc (Ireland)
- o Becton, Dickinson and Company (US)
- o LMB Technologie GmbH (Germany)
- o Bioelettronica S.r.l. (Italy)
- o Infomed SA (Switzerland)
- o Cytosorbents Corporation (US)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

o□Medicap clinic GmbH (Germany)
o□Haier Biomedical (China)
o□Beijing ZKSK Technology Co., Ltd. (China)
o□Guangzhou Daji Medical Science and Technology Co. Ltd (China)
o□PuriBlood Medical (Taiwan)

Research Coverage

This report studies the apheresis market based on product, procedure, technology, application, end user and region. The report also analyses factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total apheresis market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report

This report also includes.

- Analysis of key drivers (increasing prevalence of trauma and injury cases, rise in demand for source plasma from biopharmaceutical companies, upsurging number of complex surgical procedures, and favourable reimbursement for apheresis procedures) ,restraints (High cost of apheresis devices & therapeutic apheresis procedures and installation of apheresis devices through rental model, Fewer blood donations using apheresis due to lack of awareness, Stringent donor recruitment criteria), challenges (recruitment of voluntary non-remunerated donors, and safety of blood transfusion in developing countries), opportunities (apheresis for leukaemia and paediatric patients, and emerging economies with increasing investments from government authorities and key players) contributing the growth of the apheresis market.
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the apheresis market.
- Market Development: Comprehensive information on the lucrative emerging markets, product, procedure, technology, application, end-user and region.
- Market Diversification: Exhaustive information about the growing geographies, recent developments, investments in the apheresis market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global apheresis market.

Table of Contents:

1□INTRODUCTION□	43
1.1□STUDY OBJECTIVES□	43
1.2□MARKET DEFINITION□	43
1.2.1□PRODUCT DEFINITION□	44
1.2.2□TECHNOLOGY DEFINITION□	44
1.2.3□APPLICATION DEFINITION□	44
1.2.4□END USER DEFINITION□	45
1.2.5□INCLUSIONS & EXCLUSIONS□	46
1.3□MARKET SCOPE□	47
1.3.1□MARKETS COVERED□	47
1.3.2□REGIONS COVERED□	48
1.3.3□YEARS CONSIDERED□	48
1.3.4□CURRENCY CONSIDERED□	48
TABLE 1□CURRENCY CONVERSION RATES□	49
1.4□STAKEHOLDERS□	49
1.5□SUMMARY OF CHANGES□	49
1.6□RECESSION IMPACT□	50

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2	RESEARCH METHODOLOGY	51
2.1	RESEARCH DATA	51
FIGURE 1	RESEARCH DESIGN	51
2.1.1	SECONDARY DATA	52
2.1.1.1	Key data from secondary sources	53
2.1.2	PRIMARY DATA	54
FIGURE 2	PRIMARY SOURCES	54
2.1.2.1	Key data from primary sources	55
2.1.2.2	Key industry insights	56
FIGURE 3	BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION	56
2.2	MARKET SIZE ESTIMATION	57
FIGURE 4	MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS	57
FIGURE 5	TOP-DOWN APPROACH	58
FIGURE 6	MARKET SIZE ESTIMATION: DEMAND-SIDE ASSESSMENT	59
FIGURE 7	DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024-2029): IMPACT LEVEL	60
FIGURE 8	CAGR PROJECTIONS	60
2.3	MARKET BREAKDOWN & DATA TRIANGULATION	62
FIGURE 9	DATA TRIANGULATION METHODOLOGY	62
2.4	MARKET RANKING ANALYSIS	63
2.5	STUDY ASSUMPTIONS	63
2.6	RISK ASSESSMENT	63
2.7	LIMITATIONS	63
2.7.1	METHODOLOGY-RELATED LIMITATIONS	63
2.8	RECESSION IMPACT ANALYSIS	64
3	EXECUTIVE SUMMARY	65
FIGURE 10	APHERESIS DISPOSABLES TO BE LARGEST SEGMENT DURING FORECAST PERIOD	65
FIGURE 11	CENTRIFUGAL APHERESIS DEVICES SEGMENT TO REGISTER FASTEST GROWTH DURING FORECAST PERIOD	66
FIGURE 12	AUTOMATED BLOOD COLLECTION TO BE LEADING SEGMENT DURING FORECAST PERIOD	66
FIGURE 13	THERAPEUTIC APHERESIS DISPOSABLES TO HOLD DOMINANT SHARE BY 2029	67
FIGURE 14	NEUROLOGICAL DISORDERS TO BE LEADING SEGMENT DURING FORECAST PERIOD	67
FIGURE 15	CENTRIFUGATION TECHNOLOGY TO DOMINATE APHERESIS MARKET DURING FORECAST PERIOD	68
FIGURE 16	CONTINUOUS FLOW CENTRIFUGATION TO BE MAJOR SEGMENT DURING FORECAST PERIOD	69
FIGURE 17	PLASMAPHERESIS SEGMENT TO HOLD LARGEST SHARE BY 2029	69
FIGURE 18	COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS - MAJOR SEGMENT BY 2029	70
FIGURE 19	ASIA PACIFIC TO BE FASTEST-GROWING REGIONAL MARKET FOR APHERESIS	71
4	PREMIUM INSIGHTS	72
4.1	APHERESIS MARKET OVERVIEW	72
FIGURE 20	RIISING PREVALENCE OF DISEASES AND GROWING NUMBER OF TRAUMA AND INJURY CASES TO DRIVE MARKET GROWTH	72
4.2	EUROPE: APHERESIS MARKET, BY APPLICATION & COUNTRY	73
FIGURE 21	PLASMAPHERESIS AND GERMANY ACCOUNTED FOR LARGEST SHARE OF EUROPEAN APHERESIS MARKET IN 2023	73
4.3	REGIONAL SNAPSHOT OF APHERESIS MARKET (2023)	74
FIGURE 22	INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD	74
4.4	REGIONAL MIX: APHERESIS MARKET, 2024-2029 (USD MILLION)	75
FIGURE 23	ASIA PACIFIC MARKET TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD	75
4.5	APHERESIS MARKET: DEVELOPING VS. DEVELOPED MARKETS, 2024 VS. 2029 (USD MILLION)	75
FIGURE 24	DEVELOPING MARKETS TO REGISTER FASTER GROWTH DURING FORECAST PERIOD	75

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5	MARKET OVERVIEW	76
5.1	INTRODUCTION	76
5.2	MARKET DYNAMICS	76
	FIGURE 25 APHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	76
5.2.1	DRIVERS	77
5.2.1.1	Rising prevalence of chronic diseases and trauma/injury cases	77
	FIGURE 26 US: NUMBER OF PEOPLE WITH CHRONIC CONDITIONS, 1995-2030 (MILLION INDIVIDUALS)	78
5.2.1.2	Increasing demand for source plasma from biopharmaceutical companies	78
	FIGURE 27 EUROPE: PLASMA COLLECTION, 2012-2021 (LITERS)	79
	FIGURE 28 NORTH AMERICA: PLASMA COLLECTION, 2012-2021 (LITERS)	79
5.2.1.3	Rising demand for blood components and growing concerns regarding blood safety	79
5.2.1.4	Increase in complex surgical procedures	80
	TABLE 2 REQUIRED UNITS OF BLOOD AND BLOOD COMPONENTS, BY TYPE OF SURGERY	80
5.2.1.5	Favorable reimbursement policies for apheresis procedures	81
5.2.2	RESTRAINTS	81
5.2.2.1	High cost of procedures and installation through rental models	81
5.2.2.2	Limited use in blood donation due to low awareness	82
	TABLE 3 ESTIMATED BLOOD DONATIONS, BY REGION	82
5.2.2.3	Stringent donor recruitment criteria	82
	TABLE 4 FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS	83
5.2.2.4	Dearth of skilled professionals and low adoption of therapeutic apheresis	83
5.2.3	OPPORTUNITIES	83
5.2.3.1	Apheresis for leukemia and pediatric patients	83
5.2.3.2	Emerging economies with increasing investments from government bodies and leading players	84
5.2.4	CHALLENGES	85
5.2.4.1	Recruitment of voluntary non-remunerated donors	85
5.2.4.2	Safety of blood transfusion in developing countries	85
5.3	INDUSTRY TRENDS	86
	FIGURE 29 FOCUS ON PERSONALIZED MEDICINE, AUTOMATION, EFFICIENCY, AND EXPANSION OF APHERESIS APPLICATIONS - LEADING TRENDS	86
5.3.1	INCREASE IN FOCUS ON PERSONALIZED MEDICINE	86
5.3.2	INCREASE IN FOCUS ON AUTOMATION AND EFFICIENCY	87
5.3.3	EXPANSION OF APHERESIS APPLICATIONS	87
5.4	TECHNOLOGY ANALYSIS	88
5.4.1	KEY TECHNOLOGIES	88
5.4.1.1	Centrifugation	88
5.4.1.2	Membrane Filtration	88
5.4.1.3	Automated collection systems	89
5.4.2	COMPLEMENTARY TECHNOLOGY	89
5.4.2.1	Biocompatible Materials	89
5.4.2.2	Automation and robotics	90
5.4.2.3	Advanced imaging technologies	90
5.4.3	ADJACENT TECHNOLOGIES	91
5.4.3.1	Extracorporeal Photopheresis (ECP)	91
5.4.3.2	Continuous Renal Replacement Therapy (CRRT)	91
5.4.3.3	Hemodialysis	92
5.5	VALUE CHAIN ANALYSIS	92

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 30 APHERESIS MARKET: VALUE CHAIN ANALYSIS 93

5.6 PORTER'S FIVE FORCES ANALYSIS 93

TABLE 5 APHERESIS MARKET: PORTER'S FIVE FORCES ANALYSIS 93

5.6.1 THREAT OF NEW ENTRANTS 93

5.6.2 THREAT OF SUBSTITUTES 94

5.6.3 BARGAINING POWER OF SUPPLIERS 94

5.6.4 BARGAINING POWER OF BUYERS 94

5.6.5 INTENSITY OF COMPETITIVE RIVALRY 94

5.7 REGULATORY LANDSCAPE 95

5.7.1 REGULATORY ANALYSIS 95

5.7.1.1 North America 95

5.7.1.1.1 US 95

5.7.1.1.2 Canada 96

5.7.1.2 Europe 96

5.7.1.3 Asia Pacific 96

5.7.1.3.1 Japan 96

5.7.1.3.2 China 97

5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97

TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97

TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98

TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98

TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99

TABLE 10 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99

5.8 PATENT ANALYSIS 99

5.8.1 PATENT PUBLICATION TRENDS FOR APHERESIS MARKET 99

FIGURE 31 GLOBAL NUMBER OF PATENTS PUBLICATIONS (JANUARY 2014-MARCH 2024) 100

5.8.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 100

FIGURE 32 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR APHERESIS PATENTS (JANUARY 2014-MARCH 2024) 101

FIGURE 33 TOP APPLICANT COUNTRIES/REGIONS FOR APHERESIS (JANUARY 2013-MARCH 2024) 101

TABLE 11 LIST OF PATENTS IN APHERESIS MARKET, 2014-2024 102

5.9 HS CODES: APHERESIS INSTRUMENTS 103

TABLE 12 HS CODES FOR APHERESIS INSTRUMENTS 103

5.10 PRICING ANALYSIS 103

TABLE 13 PRICING OF APHERESIS PRODUCTS, 2023 (USD) 104

TABLE 14 PRICING ANALYSIS OF APHERESIS PRODUCTS (USD) 104

TABLE 15 REGIONAL PRICING ANALYSIS OF KEY APHERESIS PRODUCTS, 2023 (USD) 105

5.11 REIMBURSEMENT ANALYSIS 105

TABLE 16 REIMBURSEMENT ANALYSIS: FOR APHERESIS PROCEDURES 105

5.12 KEY CONFERENCES AND EVENTS, 2024-2025 106

TABLE 17 APHERESIS MARKET: KEY CONFERENCES AND EVENTS, 2024-2025 106

5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 107

5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 107

FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR APHERESIS PRODUCTS 107

TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR APHERESIS PRODUCTS 107

5.13.2 BUYING CRITERIA 107

FIGURE 35 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS 107

TABLE 19 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS 108

5.14	UNMET NEEDS IN APHERESIS MARKET	108
TABLE 20	UNMET NEEDS: APHERESIS MARKET	108
5.15	END USER EXPECTATIONS IN APHERESIS MARKET	109
TABLE 21	END USER EXPECTATIONS: APHERESIS MARKET	109
5.16	AI INTEGRATION IN APHERESIS MARKET	109
TABLE 22	AI INTEGRATION: APHERESIS MARKET	109
5.17	ECOSYSTEM ANALYSIS	110
FIGURE 36	APHERESIS MARKET: ECOSYSTEM	111
TABLE 23	ECOSYSTEM OF APHERESIS MARKET	111
5.18	CASE STUDIES	112
5.18.1	CASE STUDY 1: ESTIMATING MARKET SIZE OF LEUKAPHERESIS PRODUCTS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL	112
5.18.2	CASE STUDY 2: ESTIMATING MARKET SIZE OF LEUKOPAKS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL	112
5.18.3	CASE STUDY 3: THERAPEUTIC PLASMA EXCHANGE FOR MYASTHENIA GRAVIS	113
5.18.4	CASE STUDY 4: THERAPEUTIC APHERESIS FOR TRANSFUSION-RELATED ACUTE LUNG INJURY (TRALI)	113
5.19	SUPPLY CHAIN ANALYSIS	114
FIGURE 37	APHERESIS MARKET: SUPPLY CHAIN ANALYSIS	115
5.20	ADJACENT MARKET ANALYSIS	115
5.20.1	LEUKAPHERESIS MARKET	115
FIGURE 38	LEUKAPHERESIS PRODUCTS MARKET OVERVIEW	116
FIGURE 39	LEUKOPAKS MARKET OVERVIEW	116
5.21	APHERESIS MARKET: INVESTMENT AND FUNDING SCENARIO	116
FIGURE 40	INVESTMENT AND FUNDING SCENARIO: APHERESIS MARKET (2018-2023)	117
6	APHERESIS MARKET, BY PRODUCT	118
6.1	INTRODUCTION	119
TABLE 24	APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	119
6.2	APHERESIS DISPOSABLES	119
6.2.1	RECURRENT USE OF APHERESIS DISPOSABLES TO BOOST GROWTH	119
TABLE 25	APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	120
TABLE 26	KEY PLAYERS PROVIDING APHERESIS DISPOSABLES	120
6.3	APHERESIS DEVICES	121
TABLE 27	APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	122
TABLE 28	APHERESIS DEVICES MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	122
6.3.1	CENTRIFUGAL APHERESIS DEVICES	123
6.3.1.1	Increasing installation in hospitals for therapeutic apheresis	123
TABLE 29	CENTRIFUGAL APHERESIS DEVICES MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	124
TABLE 30	KEY PLAYERS PROVIDING CENTRIFUGAL APHERESIS DEVICES	124
6.3.2	MEMBRANE SEPARATORS	125
6.3.2.1	Separation of huge volumes of plasma from milliliters of whole blood - key limiting factor	125
TABLE 31	MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	126
TABLE 32	KEY PLAYERS PROVIDING MEMBRANE SEPARATORS	126
7	APHERESIS MARKET, BY PROCEDURE	127
7.1	INTRODUCTION	128
TABLE 33	APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	128
7.2	AUTOMATED BLOOD COLLECTION (DONOR APHERESIS)	128
7.2.1	INCREASING NUMBER OF BLOOD COMPONENT DONATIONS USING APHERESIS DEVICES TO SUPPORT MARKET GROWTH	128

TABLE 34	AUTOMATED BLOOD COLLECTION (DONOR APHERESIS), BY COUNTRY, 2021-2029 (USD MILLION)	129
7.3	THERAPEUTIC APHERESIS	129
TABLE 35	THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	130
TABLE 36	THERAPEUTIC APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	131
7.3.1	THERAPEUTIC APHERESIS DISPOSABLES	131
TABLE 37	THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	132
TABLE 38	THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	133
7.3.1.1	Neurological disorders	133
7.3.1.1.1	Hold major share in therapeutic apheresis disposables market	133
TABLE 39	NEUROLOGICAL DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	134
7.3.1.2	Blood disorders	135
7.3.1.2.1	Increasing prevalence of hematologic and genetic disorders to boost demand	135
TABLE 40	BLOOD DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	135
7.3.1.3	Renal disorders	136
7.3.1.3.1	Regarded among most useful treatment options for several renal disorders	136
TABLE 41	RENAL DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	136
7.3.1.4	Autoimmune disorders	137
7.3.1.4.1	Vital support component for treatment of autoimmune disorders	137
TABLE 42	AUTOIMMUNE DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	138
7.3.1.5	Metabolic disorders	138
7.3.1.5.1	Increasing adoption for treatment of diabetes and other metabolic disorders	138
TABLE 43	METABOLIC DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	139
7.3.1.6	Cardiovascular disorders	139
7.3.1.6.1	Low-density lipoprotein (LDL) apheresis mainly used in treatment of cardiovascular disorders	139
TABLE 44	CARDIOVASCULAR DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES, BY COUNTRY, 2021-2029 (USD MILLION)	140
7.3.1.7	Other disorders	140
TABLE 45	OTHER DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	141
7.3.2	THERAPEUTIC APHERESIS DEVICES	141
7.3.2.1	Centrifugation-based devices - most commonly adopted	141
TABLE 46	THERAPEUTIC APHERESIS DEVICES MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	142
8	APHERESIS MARKET, BY TECHNOLOGY	143
8.1	INTRODUCTION	144
TABLE 47	APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	144
8.2	CENTRIFUGATION	144
TABLE 48	CONTINUOUS FLOW CENTRIFUGATION VS. INTERMITTENT FLOW CENTRIFUGATION	144
TABLE 49	KEY PLAYERS PROVIDING CENTRIFUGATION TECHNOLOGY	145
TABLE 50	CENTRIFUGATION: APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	145
TABLE 51	CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	146
8.2.1	CONTINUOUS FLOW CENTRIFUGATION	146
8.2.1.1	Preferred in blood collection and therapeutic apheresis procedures	146
TABLE 52	CONTINUOUS FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	147
8.2.2	INTERMITTENT FLOW CENTRIFUGATION	147
8.2.2.1	Need for single venipuncture site - major driving factor	147
TABLE 53	INTERMITTENT FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	148
8.3	MEMBRANE SEPARATION	148

8.3.1	HIGH EFFICACY ACCOUNTS FOR HIGH USAGE IN DEVELOPED COUNTRIES	148
TABLE 54	SIZE OF BLOOD COMPONENTS	149
TABLE 55	KEY PLAYERS PROVIDING MEMBRANE SEPARATION TECHNOLOGY	149
TABLE 56	MEMBRANE SEPARATION: APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	150
9	APHERESIS MARKET, BY APPLICATION	151
9.1	INTRODUCTION	152
TABLE 57	APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	152
9.2	PLASMAPHERESIS	152
9.2.1	LARGEST APPLICATION SEGMENT IN APHERESIS MARKET	152
TABLE 58	PLASMAPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	154
9.3	PLATELETPHERESIS	154
9.3.1	INCREASING DEMAND FOR PLATELETS IN TRANSFUSIONS TO DRIVE GROWTH	154
TABLE 59	PLATELETPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	155
9.4	ERYTHROCYTAPHERESIS	156
9.4.1	INCREASING DEMAND FOR RED BLOOD CELLS FOR TRANSFUSION IN SURGICAL PROCEDURES TO DRIVE GROWTH	156
TABLE 60	ERYTHROCYTAPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	157
9.5	LEUKAPHERESIS	157
9.5.1	INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE SEGMENT	157
TABLE 61	LEUKAPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	158
9.6	PHOTOPHERESIS	158
9.6.1	INCREASING PREVALENCE OF BLOOD DISORDERS AND ORGAN TRANSPLANT REJECTION TO DRIVE SEGMENT	158
TABLE 62	PHOTOPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	159
9.7	OTHER APPLICATIONS	159
TABLE 63	OTHER APPLICATIONS: APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	160
10	APHERESIS MARKET, BY END USER	161
10.1	INTRODUCTION	162
TABLE 64	APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	162
10.2	BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS	162
10.2.1	INCREASING AWARENESS OF BENEFITS OF APHERESIS TO FUEL SEGMENT	162
TABLE 65	BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS: APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	163
10.3	HOSPITALS & TRANSFUSION CENTERS	163
10.3.1	RISING NUMBER OF COMPLEX SURGICAL PROCEDURES AND TRANSFUSIONS TO BOOST MARKET	163
TABLE 66	HOSPITALS & TRANSFUSION CENTERS: APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	164
10.4	OTHER END USERS	165
TABLE 67	OTHER END USERS: APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	165
11	APHERESIS MARKET, BY REGION	166
11.1	INTRODUCTION	167
FIGURE 41	APHERESIS MARKET: GEOGRAPHIC SNAPSHOT	167
TABLE 68	APHERESIS MARKET, BY REGION, 2021-2029 (USD MILLION)	168
11.2	NORTH AMERICA	168
11.2.1	NORTH AMERICA: RECESSION IMPACT	168
FIGURE 42	NORTH AMERICA: APHERESIS MARKET SNAPSHOT	169
TABLE 69	NORTH AMERICA: APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	170
TABLE 70	NORTH AMERICA: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	170
TABLE 71	NORTH AMERICA: DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	170
TABLE 72	NORTH AMERICA: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	171

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 73	NORTH AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	171
TABLE 74	NORTH AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	171
TABLE 75	NORTH AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	172
TABLE 76	NORTH AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	172
TABLE 77	NORTH AMERICA: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	172
TABLE 78	NORTH AMERICA: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	173
11.2.2	US	173
11.2.2.1	Dominates North American apheresis market	173
TABLE 79	US: KEY MACROINDICATORS	174
TABLE 80	US: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	174
TABLE 81	US: APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	174
TABLE 82	US: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	175
TABLE 83	US: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	175
TABLE 84	US: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	175
TABLE 85	US: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	176
TABLE 86	US: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	176
TABLE 87	US: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	176
TABLE 88	US: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	177
11.2.3	CANADA	177
11.2.3.1	Rising demand for plasma protein products to drive market growth	177
TABLE 89	CANADA: KEY MACROINDICATORS	178
TABLE 90	CANADA: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	178
TABLE 91	CANADA: APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	178
TABLE 92	CANADA: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	179
TABLE 93	CANADA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	179
TABLE 94	CANADA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	179
TABLE 95	CANADA: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	180
TABLE 96	CANADA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	180
TABLE 97	CANADA: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	180
TABLE 98	CANADA: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	181
11.3	EUROPE	181
11.3.1	EUROPE: RECESSION IMPACT	182
TABLE 99	EUROPE: APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	182
TABLE 100	EUROPE: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	182
TABLE 101	EUROPE: APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	183
TABLE 102	EUROPE: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	183
TABLE 103	EUROPE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	183
TABLE 104	EUROPE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	184
TABLE 105	EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	184
TABLE 106	EUROPE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	184
TABLE 107	EUROPE: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	185
TABLE 108	EUROPE: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	185
11.3.2	GERMANY	185
11.3.2.1	Fastest-growing market for apheresis systems in Europe	185
TABLE 109	GERMANY: KEY MACROINDICATORS	186
TABLE 110	GERMANY: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	186
TABLE 111	GERMANY: APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	186

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 112	GERMANY: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	187
TABLE 113	GERMANY: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	187
TABLE 114	GERMANY: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	187
TABLE 115	GERMANY: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	188
TABLE 116	GERMANY: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	188
TABLE 117	GERMANY: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	188
TABLE 118	GERMANY: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	189
11.3.3	FRANCE	189
11.3.3.1	Increasing need for blood components to boost market	189
TABLE 119	FRANCE: KEY MACROINDICATORS	189
TABLE 120	FRANCE: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	190
TABLE 121	FRANCE: APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	190
TABLE 122	FRANCE: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	190
TABLE 123	FRANCE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	191
TABLE 124	FRANCE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	191
TABLE 125	FRANCE: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	191
TABLE 126	FRANCE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	192
TABLE 127	FRANCE: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	192
TABLE 128	FRANCE: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	192
11.3.4	ITALY	193
11.3.4.1	Therapeutic plasma exchange and LDL apheresis - widely adopted procedures	193
TABLE 129	ITALY: KEY MACROINDICATORS	193
TABLE 130	ITALY: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	193
TABLE 131	ITALY: APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	194
TABLE 132	ITALY: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	194
TABLE 133	ITALY: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	194
TABLE 134	ITALY: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	195
TABLE 135	ITALY: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	195
TABLE 136	ITALY: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	195
TABLE 137	ITALY: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	196
TABLE 138	ITALY: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	196
11.3.5	UK	196
11.3.5.1	Growing consumption of plasma-derived products to fuel market growth	196
TABLE 139	UK: KEY MACROINDICATORS	197
TABLE 140	UK: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	197
TABLE 141	UK: APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	198
TABLE 142	UK: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	198
TABLE 143	UK: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2021-2029 (USD MILLION)	198
TABLE 144	UK: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	199
TABLE 145	UK: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	199
TABLE 146	UK: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	199
TABLE 147	UK: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	200
TABLE 148	UK: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	200
11.3.6	SPAIN	200
11.3.6.1	Growing demand for treatment of chronic diseases in the elderly	200
TABLE 149	SPAIN: KEY MACROINDICATORS	201
TABLE 150	SPAIN: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	201

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 151	SPAIN: APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	201
TABLE 152	SPAIN: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	202
TABLE 153	SPAIN: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	202
TABLE 154	SPAIN: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	202
TABLE 155	SPAIN: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	203
TABLE 156	SPAIN: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	203
TABLE 157	SPAIN: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	203
TABLE 158	SPAIN: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	204
11.3.7	REST OF EUROPE	204
TABLE 159	REST OF EUROPE: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	205
TABLE 160	REST OF EUROPE: APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	205
TABLE 161	REST OF EUROPE: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	205
TABLE 162	REST OF EUROPE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	206
TABLE 163	REST OF EUROPE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	206
TABLE 164	REST OF EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	206
TABLE 165	REST OF EUROPE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	207
TABLE 166	REST OF EUROPE: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	207
TABLE 167	REST OF EUROPE: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	207
11.4	ASIA PACIFIC	208
11.4.1	ASIA PACIFIC: RECESSION IMPACT	208
FIGURE 43	ASIA PACIFIC: APHERESIS MARKET SNAPSHOT	209
TABLE 168	ASIA PACIFIC: APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	210
TABLE 169	ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	210
TABLE 170	ASIA PACIFIC: APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	210
TABLE 171	ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	211
TABLE 172	ASIA PACIFIC: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	211
TABLE 173	ASIA PACIFIC: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	211
TABLE 174	ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	212
TABLE 175	ASIA PACIFIC: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	212
TABLE 176	ASIA PACIFIC: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	212
TABLE 177	ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	213
11.4.2	CHINA	213
11.4.2.1	Dominant Asia Pacific apheresis market	213
TABLE 178	CHINA: KEY MACROINDICATORS	213
TABLE 179	CHINA: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	214
TABLE 180	CHINA: APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	214
TABLE 181	CHINA: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	214
TABLE 182	CHINA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	215
TABLE 183	CHINA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	215
TABLE 184	CHINA: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	215
TABLE 185	CHINA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	216
TABLE 186	CHINA: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	216
TABLE 187	CHINA: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	216
11.4.3	JAPAN	217
11.4.3.1	Advanced technology and universal healthcare insurance - key drivers	217
TABLE 188	JAPAN: KEY MACROINDICATORS	217
TABLE 189	JAPAN: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	217

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 190	JAPAN: APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	218
TABLE 191	JAPAN: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	218
TABLE 192	JAPAN: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	218
TABLE 193	JAPAN: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	219
TABLE 194	JAPAN: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	219
TABLE 195	JAPAN: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	219
TABLE 196	JAPAN: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	220
TABLE 197	JAPAN: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	220
11.4.4	INDIA	220
11.4.4.1	Increasing demand for blood components and growing applications of plasma derivatives - key drivers	220
TABLE 198	INDIA: KEY MACROINDICATORS	221
TABLE 199	INDIA: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	221
TABLE 200	INDIA: APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	221
TABLE 201	INDIA: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	222
TABLE 202	INDIA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	222
TABLE 203	INDIA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	222
TABLE 204	INDIA: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	223
TABLE 205	INDIA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	223
TABLE 206	INDIA: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	223
TABLE 207	INDIA: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	224
11.4.5	AUSTRALIA	224
11.4.5.1	Growing awareness campaigns to drive market growth	224
TABLE 208	AUSTRALIA: KEY MACROINDICATORS	224
TABLE 209	AUSTRALIA: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	225
TABLE 210	AUSTRALIA: APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	225
TABLE 211	AUSTRALIA: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	225
TABLE 212	AUSTRALIA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	226
TABLE 213	AUSTRALIA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	226
TABLE 214	AUSTRALIA: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	226
TABLE 215	AUSTRALIA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	227
TABLE 216	AUSTRALIA: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	227
TABLE 217	AUSTRALIA: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	227
11.4.6	SOUTH KOREA	228
11.4.6.1	Rise in prevalence of blood cancers to drive market growth	228
TABLE 218	SOUTH KOREA: KEY MACROINDICATORS	228
TABLE 219	SOUTH KOREA: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	228
TABLE 220	SOUTH KOREA: APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	229
TABLE 221	SOUTH KOREA: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	229
TABLE 222	SOUTH KOREA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	229
TABLE 223	SOUTH KOREA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	230
TABLE 224	SOUTH KOREA: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	230
TABLE 225	SOUTH KOREA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	230
TABLE 226	SOUTH KOREA: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	231
TABLE 227	SOUTH KOREA: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	231
11.4.7	REST OF ASIA PACIFIC	231
TABLE 228	REST OF ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	232
TABLE 229	REST OF ASIA PACIFIC: APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	232

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 230	REST OF ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	232
TABLE 231	REST OF ASIA PACIFIC: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	233
TABLE 232	REST OF ASIA PACIFIC: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	233
TABLE 233	REST OF ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	233
TABLE 234	REST OF ASIA PACIFIC: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	234
TABLE 235	REST OF ASIA PACIFIC: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	234
TABLE 236	REST OF ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	234
11.5	LATIN AMERICA	235
11.5.1	LATIN AMERICA: RECESSION IMPACT	235
TABLE 237	LATIN AMERICA: APHERESIS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	235
TABLE 238	LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	236
TABLE 239	LATIN AMERICA: APHERESIS DEVICES MARKET, BY TYPE, 2021-2029 (USD MILLION)	236
TABLE 240	LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2021-2029 (USD MILLION)	236
TABLE 241	LATIN AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021-2029 (USD MILLION)	237
TABLE 242	LATIN AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021-2029 (USD MILLION)	237
TABLE 243	LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	237
TABLE 244	LATIN AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021-2029 (USD MILLION)	238
TABLE 245	LATIN AMERICA: APHERESIS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)	238
TABLE 246	LATIN AMERICA: APHERESIS MARKET, BY END USER, 2021-2029 (USD MILLION)	238

Apheresis Market Size by Product (Device (Centrifugation, Membrane Separation) Disposable), Procedure (Donor, Therapeutic), Application (Plasmapheresis, Plateletpheresis), Technology, End-User (Hospital, Blood Collection Center), Region - Global Forecast to 2029

Market Report | 2024-04-12 | 330 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-05-20
		Signature	<div></div>